Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Intracoronary glycoprotein IIb/IIIa inhibitor infusion via a perfusion coronary catheter to decrease thrombus burden: results from the ClearWay™ Multicenter Registry.

Maluenda G, Sizemore BC, Revtyak G, Cavros N, McElroy BB, Arora DS, Deibele A, Makam S, Ben-Dor I, Torguson R, Waksman R; Clearway Registry Investigators.

Cardiovasc Revasc Med. 2013 Sep-Oct;14(5):280-3. doi: 10.1016/j.carrev.2012.12.006. Epub 2013 Jan 30.

PMID:
23375788
2.

[Intracoronary administration of antithrombotic agents via a perfusion balloon catheter in patients with ST-segment elevation myocardial infarction presenting with massive intraluminal thrombus and failed aspiration].

Ajlani B, Gibault-Genty G, Cherif G, Blicq E, Azzaz S, Schiano P, Brami M, Sarfati L, Charbonnel C, Convers-Domart R, Livarek B, Georges JL.

Ann Cardiol Angeiol (Paris). 2016 Nov;65(5):299-305. doi: 10.1016/j.ancard.2016.09.009. Epub 2016 Sep 29. French.

PMID:
27693166
3.

'Mother-in-child' thrombectomy technique: a novel and effective approach to decrease intracoronary thrombus burden in acute myocardial infarction.

Dauvergne C, Araya M, Uriarte P, Novoa O, Novoa L, Maluenda G.

Cardiovasc Revasc Med. 2013 Jan-Feb;14(1):14-7. doi: 10.1016/j.carrev.2012.10.010. Epub 2012 Dec 21.

PMID:
23265854
4.

The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.

Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group.

Catheter Cardiovasc Interv. 2012 May 1;79(6):956-64. doi: 10.1002/ccd.23165. Epub 2011 Dec 12.

PMID:
22162050
5.

Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.

De Luca G, Gibson M, Cutlip D, Huber K, Dudek D, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Secco GG, Mesquita Gabriel H, Emre A, Arntz HR, Rakowski T, Gyongyosi M, Hof AW; EGYPT Cooperation.

Arch Cardiovasc Dis. 2013 Mar;106(3):155-61. doi: 10.1016/j.acvd.2012.12.007. Epub 2013 Apr 2.

6.

Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.

Zhang Q, Wang XL, Liao ML, Hu J, Yang ZK, Ding FH, Zhang JS, Du R, Zhu TQ, Shen WF, Zhang RY.

Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:762-9. doi: 10.1002/ccd.25864.

PMID:
25630513
8.

Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCTAIL II study.

Prati F, Di Vito L, Ramazzotti V, Imola F, Pawlowski T, Materia L, Tavazzi L, Biondi-Zoccai G, Albertucci M.

J Cardiovasc Med (Hagerstown). 2013 May;14(5):364-71. doi: 10.2459/JCM.0b013e3283586fee.

PMID:
22929568
9.
10.

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM.

JACC Cardiovasc Interv. 2013 Jul;6(7):671-83. doi: 10.1016/j.jcin.2013.03.014.

11.

Angiographic characteristics of definite stent thrombosis: role of thrombus grade, collaterals, epicardial coronary flow, and myocardial perfusion.

Reeves RR, Patel M, Armstrong EJ, Sab S, Waldo SW, Yeo KK, Shunk KA, Low RI, Rogers JH, Mahmud E.

Catheter Cardiovasc Interv. 2015 Jan 1;85(1):13-22. doi: 10.1002/ccd.25519. Epub 2014 May 7.

PMID:
24753053
12.
13.

A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.

Sardella G, Sangiorgi GM, Mancone M, Colantonio R, Donahue M, Politi L, Bucciarelli-Ducci C, Carbone I, Francone M, Ligabue G, Fiocchi F, Di Roma A, Benedetti G, Lucisano L, Stio RE, Agati L, Modena MG, Genuini I, Fedele F, Gibson M.

J Cardiovasc Med (Hagerstown). 2010 Jul;11(7):529-35. doi: 10.2459/JCM.0b013e3283341c1c. Erratum in: J Cardiovasc Med (Hagerstown). 2015 Apr;16(4):320. Ducci, Chiara B [corrected to Bucciarelli-Ducci, C].

PMID:
19918189
14.

Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review.

Ali-Hasan-Al-Saegh S, Mirhosseini SJ, Shahidzadeh A, Rahimizadeh E, Sarrafan-Chaharsoughi Z, Ghodratipour Z, Lotfaliani M, Rezaeisadrabadi M, Dehghan HR, Bireta C, Weymann A, Sabashnikov A, Popov AF.

Kardiol Pol. 2016;74(2):104-18. doi: 10.5603/KP.a2015.0138. Epub 2015 Jul 23. Review.

15.

Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function.

Pellicori P, Torromeo C, Barillà F, Mangieri E, Evangelista A, Truscelli G, Costanzo P, Hoye A, Wong K.

Cardiol J. 2013;20(3):310-7. doi: 10.5603/CJ.2013.0077.

16.

Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.

Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, Todaro D, Giammarinaro M, Leone AM, Niccoli G, Andreotti F, Mazzari MA, Schiavoni G, Crea F.

J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):245-51. doi: 10.2459/JCM.0b013e32832180d9.

PMID:
19262211
17.

Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.

Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW.

Am Heart J. 2011 Mar;161(3):478-486.e7. doi: 10.1016/j.ahj.2010.10.006. Epub 2011 Jan 28.

PMID:
21392601
18.

Comparison of different strategies for acute ST-segment elevation myocardial infarction with high thrombus burden in clinical practice: Symptom-free outcome at one year.

Lee WC, Chen HC, Fang HY, Hsueh SK, Chen CJ, Yang CH, Yip HK, Wu CJ, Fang CY, Hang CL.

Heart Lung. 2015 Nov-Dec;44(6):487-93. doi: 10.1016/j.hrtlng.2015.08.003.

PMID:
26572772
19.

Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.

Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators.

JACC Cardiovasc Interv. 2012 Sep;5(9):927-35. doi: 10.1016/j.jcin.2012.05.007.

20.

Thrombus aspiration with export catheter in ST elevation myocardial infarction.

Margheri M, Vittori G, Chechi T, Falchetti E, Cosgrave J, Spaziani G, Ricceri I, Giglioli C, Valente S, Gensini GF.

J Interv Cardiol. 2007 Feb;20(1):38-43.

PMID:
17300401

Supplemental Content

Support Center